Pre-clinical experimental models of rhinovirus (RV)-induced exacerbations of allergic asthma have been used to test the eventual therapeutic efficacy of an anti-IL-25 monoclonal antibody (ABM125) [109]. The gene discussed is IL25; the disease is allergic asthma.